Table 5. Benchmarks from baseline group and the positive case number (over benchmarks) in baseline and MDS group.
| Antigens * | Benchmark (Cut-off) | Baseline group (n = 85) | MDS group (n = 180) | |||
| Low-grade with normal Karyotype (n = 88) | Low-grade with abnormal Karyotype (n = 38) | High-grade MDS (n = 54) | P value | |||
| CD34/CD45 | 1.8% | 4 (4.7%) | 14 (15.9%) | 14 (36.8%) | 48 (88.9%) | P<0.001 |
| CD19/CD34 | 7.0% | 16 (18.8%) | 37 (42.0%) | 22 (57.9%) | 50 (92.6%) | P<0.001 |
| CD38/CD34 | 364 | 8 (9.4%) | 35 (39.8%) | 17 (44.7%) | 37 (68.5%) | P = 0.003 |
| CD117/CD34 | 85.0% | 15 (17.6%) | 37 (42.0%) | 24 (63.1%) | 50 (92.6%) | P<0.001 |
| CD7/CD34 | 21.2% | 3 (3.5%) | 29 (33.0%) | 7 (18.4%) | 13 (24.1%) | P = 0.200 |
| CD15/CD34 | 30.8% | 7 (8.2%) | 47 (53.4%) | 12 (31.6%) | 8 (16.7%) | P<0.001 |
| CD11b/CD34 | 35.6% | 9 (10.6%) | 54 (61.4%) | 17 (44.7%) | 10 (18.5%) | P<0.001 |
| CD4/CD34 | 21.2% | 5 (5.9%) | 41 (46.6%) | 12 (31.6%) | 10 (18.5%) | P = 0.003 |
| CD56/CD34 | 20.7% | 6 (7.1%) | 56 (63.6%) | 18 (47.4%) | 14 (25.9%) | P<0.001 |
*CD34/CD45 indicates the proportion of CD34+ blasts in marrow total nucleated cells with CD45 positive.
CD19/CD34, CD117/CD34 and CD7/CD34 represent the expressive proportion of CD19/CD117/CD7 in CD34+ blasts; CD38/CD34 represents RMFI of CD38 expression in CD34+ blasts. For CD34 and CD19, the cut-off values calculated by ROC curve are defined as the benchmark. For CD38, CD117, CD7, CD15, CD11b, CD4 and CD56, the mean value of the proportions of immunophenotypes of the baseline group plus two times the standard deviation (Mean +2SD) was defined as the benchmark. If any of the tested value was higher than the benchmark, it was defined as positive.